Does PALI pay a dividend and is it safe?

Palisade Bio Inc. (PALI) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / PALI / dividends

ARTV (27) PLX (23) DTIL (30) IKT (29) ⌘ Pro Terminal →

Palisade Bio Inc. (PALI) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.12 -3.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.11

Palisade Bio Inc. (PALI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $202.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PALI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PALI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Palisade Bio Inc. (NASDAQ: PALI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.12 (-3.45% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PALI compare to ARTV and PLX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PALI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M) and PLX (Protalix BioTherapeutics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -13.0%, cap $208.7M). Among the 5-stock peer group, PALI leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PALI?

▼

Per PALI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357459), Palisade Bio Inc. generated $50.6M in revenue (+21.5% YoY), -$16.8M in net income, and -$10.8M in free cash flow against $134.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.11 (-0.81%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PALI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY PALI SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.59-15.7% Next Q

Q2 (-2Q)

Grade E$1.34-8.2% Next Q

Q3 (-1Q)

Grade E$1.23-8.9% Next Q

Current

Grade E$1.12-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PALI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PALI currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.18) forces dealer call-delta covering toward $3.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PALI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PALI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PALI)

✓Walkthrough of PALI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PALI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.42%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.19H $1.19L $1.12C $1.12VOL 3.09M

RES: $2.20SUP: $1.07SMA50: $1.64SMA200: $1.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PALI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PALI Butterfly Map → + Track PALI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PALI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PALI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PALI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PALI)

Health Care Rank #718 of 1016 ⚔️ ARTV vs PALI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PALI vs. ARTV, PLX, DTIL, IKT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Palisade Bio Inc. (PALI) ranks #718 by composite RQD confidence (32/100, grade E) and #573 by equity capitalization ($202.2M). Within this direct 5-issuer industry benchmark cohort, PALI leads on earnings valuation at N/A trailing P/E, while PLX leads on capital efficiency and profitability with -13.0% ROIC and 48.8% gross margin. PALI currently leads its immediate peer cohort in composite quantitative strength at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PALI ACTIVE Palisade Bio Inc.	E	32/100	—	—	-35.0%	-3.45%	$202.2M	Benchmark Subject
ARTV Artiva Biotherapeutics Inc.	E	27/100	—	—	-35.0%	0.00%	$204.8M	/artv-vs-pali →
PLX Protalix BioTherapeutics Inc.	E	23/100	—	48.8%	-13.0%	-1.16%	$208.7M	/plx-vs-pali →
DTIL Precision BioSciences Inc.	E	30/100	—	—	-35.0%	-1.56%	$194.9M	/dtil-vs-pali →
IKT Inhibikase Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.64%	$216.3M	/ikt-vs-pali →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001357459

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Palisade Bio Inc. (PALI) reported GAAP revenue of $50.6M (+21.5% vs. FY2024 revenue of $41.6M , and +20122.7% cumulative change since FY2023) , GAAP net income of -$16.8M, operating cash flow of -$10.8M, and free cash flow of -$10.8M (+11.0% YoY). On the balance sheet, PALI closed FY2025 with $134.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$50.6M	-$16.8M	-$10.8M	-$10.8M	$134.3M	—
FY2024 (FY)	2024-12-31	$41.6M	-$14.4M	-$12.2M	-$12.2M	$10.9M	—
FY2023 (FY)	2023-12-31	$250.0K	-$12.3M	-$11.1M	-$11.1M	—	—

3. PALI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PALI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PALI compare to ARTV and PLX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PALI?

Where is PALI trading relative to its 50-day, 200-day, and 52-week technical levels?

PALI last traded at $1.12 (-3.45% on volume of 3,073,062 shares), positioning the stock -31.71% below its 50-day simple moving average ($1.64) and -39.46% below its 200-day simple moving average ($1.85). Across its 52-week range of $1.10 to $2.86, PALI sits at the 1.1% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.26).

Direct Sub-Reports: PALI RQD Cockpit PALI 12M Forecast PALI Earnings & Move PALI Dividends & DRIP PALI Insiders & 13F PALI Whale Options PALI Profit Sankey PALI News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PALI — Palisade Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:58Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

PALI scores 43 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC of -35%; FCF yield of -5.23%); Whale 13F Flow at 9/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 12/20 (beta of 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z of 2.5; Piotroski F of 2/9; Debt/Equity of 0.5). For a prospective investor, the weakest pillars are insider conviction and the cash engine. The fundamental pillar reflects negative return on invested capital and negative free cash flow yield, meaning the company is not currently generating cash returns on the capital deployed. The forensic pillar is middling rather than distressed, with a Piotroski score of 2 out of 9 signaling weak fundamental quality. Upside drivers cited in the source data are limited to the news flow and institutional activity noted below; the rating itself frames the near-term setup as vulnerable. This analysis is educational and is not personalized financial advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

Palisade Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..2B. Reported revenue is — in FY 2025 and FY 2024 and $0.2M in FY 2023, .

The company reported operating losses in each period shown, with margins of 0% across gross, operating, and net measures per the market data. ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, both as referenced in the Roarable RQD rating. Reported cash rose to $133.4M in FY 2025 from $9.8M in FY 2024, and debt is listed as N/A in the filings provided, with a Debt/Equity ratio of 0.5 per the RQD rating.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Reported cash rose to $133.4M in FY 2025 from $9.8M in FY 2024, and H.C. Wainwright reiterated a buy rating on the stock. With Fundamental Cash Engine at 9/20 (ROIC -35.0%, FCF yield -5.23%) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.10 – $2.86 52-week range.
🐻 Primary Bear Case: The RQD score of 43 (D-, Roarable Sell) reflects an ROIC of -35%, a free cash flow yield of -5.23%, and a Piotroski F-Score of 2 out of 9. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), PALI carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: What products or pipeline assets does the company hold, and what stage are they at?
Key Question #2: What are the terms and timing of the cash position reported at $133.4M in FY 2025, given cash of $9.8M in FY 2024?
Key Question #3: What is the debt structure behind the Debt/Equity ratio of 0.5, given that debt is listed as N/A?

PALI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Palisade Bio Inc. (PALI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PALI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 20h ago

Palisade Bio, Inc. (PALI) stock price, news, quote and history

Yahoo Finance Singapore report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 23h ago

H.C. Wainwright reiterates Palisade Bio stock rating at buy

Investing.com report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Palisade Bio (Nasdaq:PALI) - Stock Analysis

Simply Wall St report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A gut inflammation marker fell 58.8% in five patients after 14 days on Palisade Bio’s experimental drug.

Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Counsel receives 787,300 stock units at Palisade Bio (PALI), subject to service-based vesting.

Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Palisade Bio's US$26m Market Cap Fall Books Insider Losses

Simply Wall St report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Palisade Bio (PALI) Holds Above $1.37 Support as Shares Edge Up 0.70% to $1.44 - Total Put Call

https://www.dars.gov.et/ report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

PALISADE BIO, INC. Initial Statement of Beneficial Ownership

Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PALI Bull vs. Bear Conversation Board — What's Your Call at $1.12?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PALI 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.43 (+23.3%)

📌 Pinned Debate

Reported cash rose to $133.4M in FY 2025 from $9.8M in FY 2024, and H.C. Wainwright reiterated a buy rating on the stock.

The street is overcomplicating Palisade Bio Inc. (PALI). Reported cash rose to $133.4M in FY 2025 from $9.8M in FY 2024, and H.C. Wainwright reiterated a buy rating on the stock.. With an RQD score of 32/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.25.

RetailWhale_TX 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $1.16 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.96 (-17.2%)

Spot @ $1.16

The RQD score of 43 (D-, Roarable Sell) reflects an ROIC of -35%, a free cash flow yield of -5.23%, and a Piotroski F-Score of 2 out of

The RQD score of 43 (D-, Roarable Sell) reflects an ROIC of -35%, a free cash flow yield of -5.23%, and a Piotroski F-Score of 2 out of 9.. Look at the math on PALI: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $1.02 before getting long.